Breaking AI & Tech News Analyzed

Romanian director Radu Jude is known for his wildly improvised and low-budget filmmaking style, often incorporating elements of TV ads, AI-generated content, and amateur dramatics into his movies. His latest film, 'Dracula', continues this trend, presenting a satirical take on Romania's dark past and the country's most reliable export: the legend of Dracula. The film is a meta-cinematic experiment, featuring a smug and supercilious film-maker, Adonis Tanta, who introduces the audience to his cheapo film about Dracula, created on his iPad using unbearable AI. The story is interspersed with set-piece mini-films-within-a-film on Dracula-adjacent themes, including a communist-era tale of a truck driver who falls in love with a local woman. Jude's film is a scathing critique of Romania's persistent strains of fascism, antisemitism, clerical arrogance, exploitative service economy, and stakeholder capitalism. Specifically, it relates to a proposal for a Dracula theme park in the late 1990s, in which thousands of Romanian citizens invested money that they would never see again. While the film may test the audience's patience at times, it features moments of startling insanity and is a testament to Jude's innovative filmmaking style. As the reviewer notes, 'one day, I predict, Jude will make a biopic of political vampirism about the most pressing Romanian subject of all: Nicolae and Elena Ceaușescu.' 'Dracula' is set to premiere at the ICA in London on April 10.

Italian Prime Minister Giorgia Meloni recently visited Qatar, meeting with Emir Sheikh Tamim bin Hamad Al Thani to address pressing energy concerns amid the ongoing conflict between Iran, the United States, and Israel. This meeting marks a significant step in Italy's efforts to bolster its relationships with key Gulf nations and ensure a stable energy supply.The discussions between Meloni and the Qatari leader focused on energy issues and potential measures to mitigate the shocks caused by the Iran war. Italy, being highly dependent on energy imports, is particularly concerned about the rising energy prices resulting from Iran's effective blocking of the Strait of Hormuz, a critical waterway through which approximately 20 percent of global oil and liquefied natural gas transits.During the meeting, Meloni expressed Italy's readiness to contribute to the rehabilitation of Qatari energy infrastructure, which is essential for global energy security. This commitment underscores Italy's proactive approach to addressing the energy crisis and its willingness to collaborate with Qatar to ensure a stable energy supply.The Qatari Emir's office stated that both sides stressed the need for de-escalation and prioritized political dialogue and diplomacy to contain the current crisis in the Middle East and its repercussions on energy and supply chains. They also reviewed bilateral cooperation between Italy and Qatar, exploring ways to support and develop it in various fields, particularly in the economy and energy sectors.Since the beginning of the war at the end of February, Iran has targeted US and Israeli targets in the region, as well as Gulf countries, including Qatar. Iran's attacks on Qatar's energy installations, such as the missile strike on Ras Laffan Industrial City, have caused significant damage and are expected to affect Doha's natural gas export capacity.Meloni's trip to the Gulf aimed to strengthen relations with these countries and reiterate Italy's support against Iranian attacks. As the first leader of a European Union or NATO country to travel to the region since the war broke out, Meloni's visit underscores Italy's commitment to regional stability and energy security.

Indonesia formally received the coffins of three United Nations peacekeepers who lost their lives in southern Lebanon as Israel intensified its invasion, a development that underscores the expanding regional fallout of the US‑Israel war on Iran. On Saturday, uniformed officers carried the bodies into a solemn ceremony attended by President Prabowo Subianto. Following the tribute, Foreign Minister Sugiono urged a comprehensive UN inquiry into the fatalities, stressing that "incidents like this should not happen" and calling for a security guarantee for peacekeeping troops. The three soldiers—Farizal Rhomadhon (28), Zulmi Aditya Iskandar (33) and Muhammad Nur Ichwan (26)—were members of the United Nations Interim Force in Lebanon (UNIFIL). Rhomadhon was killed when a projectile, later attributed by a UN source to fire from an Israeli tank, detonated near his position. A day later, Iskandar and Ichwan perished in an explosion that struck a UNIFIL logistics convoy. Family members expressed deep sorrow. Iskandar’s father, Iskandarudin (60), told reporters from West Java that the loss was especially painful because the troops were deployed for peace, not combat. The government announced that the trio will be interred on Sunday and pledged financial assistance to their families, reflecting Indonesia’s commitment to support the bereaved. In a related incident, UNIFIL reported that three additional peacekeepers were wounded in a blast at a facility near Adeisse; the cause of that explosion remains unidentified, though the injured were confirmed to be Indonesian. Indonesia’s foreign ministry has called on the UN Security Council to convene an urgent meeting of troop‑contributing nations to review and strengthen protection measures for UNIFIL personnel. The tragedy occurs against the backdrop of a broader conflict: the US‑Israel offensive against Iran has spilled into Lebanon after Hezbollah, aligned with Tehran, launched rockets following the assassination of Iran’s Supreme Leader Ayatollah Ali Khamenei on 28 February. Israeli forces have been bombarding Lebanon for weeks, aiming to establish a 30 km (≈18.6 mi) security zone along the border. Key takeaway: The loss of Indonesian peacekeepers highlights the heightened risks faced by UN missions in volatile theaters and intensifies calls for stronger international safeguards amid escalating Middle‑East hostilities.

In December and January, researchers from the Bob Brown Foundation recorded the unmistakable call of the swift parrot – the world’s fastest bird – in a section of the Wielangta forest, southeast Tasmania, that had already been earmarked for clear‑felling.Dr Charley Gros, a lead scientist on the project, described the call as “tiny but very loud, sharp and quick,” making it easy to distinguish from other forest sounds. Over a two‑month period, the team – assisted by volunteer citizen scientists – logged 68 separate observations, which were later vetted by a government scientist and uploaded to the state environment department’s database.Gros argued that the frequency of detections indicated the area was being used for foraging and nesting, not merely as a fly‑by corridor. “If they’re there every day, that is their habitat,” he said.When the recordings were submitted, the Forest Practices Authority dispatched an ecologist to the site (identified as coupe WT003E) on 10 February. The official report stated that “no swift parrots were observed breeding in the harvest area.” By that time, the forest patch had already been cleared, which Gros noted made the absence of birds unsurprising.The logging operation was carried out by Sustainable Timber Tasmania (formerly Forestry Tasmania). The agency maintained that it operated “within Tasmania’s strict forest‑practice framework” and that “nesting trees are retained and harvested areas are regenerated as native forest,” asserting compliance with environmental regulations.The incident revives a broader debate over whether existing legislation adequately safeguards threatened species. Critics point to the swift parrot’s precipitous decline – a CSIRO‑published guide in 2021 estimated the population at about 750 individuals, down from roughly 2,000 a decade earlier – and warn that without stronger protection the bird could be extinct by the early 2030s. Forestry remains identified as the greatest threat, though government officials have historically downplayed the link.The Bob Brown Foundation accused both state and federal governments of “blatantly ignoring scientific advice” and allowing logging that drives the species toward extinction. A Tasmanian government spokesperson countered that the state’s “science‑based forest practices system” prohibits deforestation of swift‑parrot habitat, emphasizing that regenerated forests will provide future flowering eucalypts.At the federal level, a spokesperson for the Albanese government noted that a regional forestry agreement places responsibility for habitat protection on Tasmania, but an exemption for state‑run forestry from national environmental law expires in 2027. After that date, any logging that significantly impacts threatened species would require approval from Canberra.Environmental campaigners, including the Wilderness Society, have intensified pressure on retailers such as Bunnings to stop sourcing timber from the contested coupe. The society argues that the forest‑certification program awarded to logs from WT003E does not guarantee sustainable practices. Alice Hardinge, the Wilderness Society’s Tasmanian campaigns manager, warned that “customers don’t want to be sold timber that destroys unique forests and pushes the swift parrot to extinction.”Bunnings responded that an internal review found “no evidence to indicate non‑compliance with Tasmanian environmental or logging laws at this site,” reaffirming its commitment to sourcing wood from compliant, well‑managed operations.

When screenwriter Daisy Goodwin examined Prince Albert’s habit of selecting Victoria’s bonnets, she wondered whether the gesture signified tender devotion or a more unsettling dominance. The question becomes the backbone of her new stage drama, which recasts the iconic Victorian marriage as a case of coercive control rather than a model partnership. Set in the waning days of Victoria’s reign at Windsor, the production opens with Amanda Boxer portraying an aging monarch—a weary, self‑pitying figure cloaked in black bombazine. Her character, a compulsive diarist, fears that her candid journals might be released after her death, a concern that fuels the play’s tension. Designer Alex Berry creates a slanted, reflective ceiling that acts like a distorted mirror of memory, underscoring Victoria’s claim that her diaries are “the only place where I could be completely honest”. Yet the presence of Albert, played by Rowan Polonski, suggests that even these private pages were never truly safe. Jessica Rhodes brings youthful Victoria to life, initially buoyant as she waltzes with Albert. The romance quickly darkens as Albert’s behavior shifts to manipulating her ambitions and curbing her joy. He pressures her into motherhood—she dismisses the children as “invincibly tedious”—and intrudes on her official duties, from speeches to industrial tours. In a biting line, she accuses him of making “the monarchy so boring that no one was awake enough to start a revolution”. The play’s narrative moves from teasing banter to overt control, with intimate moments on the sofa devolving into fierce arguments over gifts (“You gave me a brooch made of teeth, Albert!”). A poignant scene where Victoria reads from Jane Eyre hints at a gothic destiny that Goodwin imagines Albert may have plotted. While Goodwin’s empathy clearly leans toward Victoria, the production also raises contemporary expectations of royalty, suggesting that public service—not romantic idealisation—should define modern monarchs. Director Sophie Drake’s brisk pacing navigates the play’s contradictions, ultimately unsettling the long‑held myth of a contented, untroubled royal household. The production runs at the Watermill Theatre in Newbury until 9 May, offering audiences a fresh, critical lens on a celebrated historical partnership.

In a viral trend on TikTok, Londoners are reviewing upmarket bakeries and cafes in their neighborhoods, sparking conversations about gentrification and the changing face of local businesses.Moses Combe, a 21-year-old from north London, started a series of videos called the 'Endz Department for Research', where he reviews upscale cafes that he wouldn't normally visit. His goal is to investigate the changes happening in his own backyard. Combe's review of Jolene, a bakery he describes as 'giving Gail's Pro Max', comes to £14.20. He enjoys the sausage roll, saying 'They did not skimp out with that sausage, bro.'Combe isn't alone in his reviews. Kobi Coker, a 27-year-old comedian and educator, also reviews 'gentrified' spaces. He says his videos exploring these areas weren't initially intentional but were sparked by noticing new, upmarket establishments opening up on his road during his daily commute. Coker has reviewed the Dusty Knuckle bakery, Jolene, Gail's, and Pret, often joking about his experiences.The trend has led to discussions about gentrification and its impact on local businesses. Coker notes that while some new businesses bring new ideas, the problem is that long-time residents 'aren't necessarily able to participate in it.' Matthew Roberts, operations manager at Jolene, welcomes the attention, saying it's 'all very positive' and that they want to 'welcome absolutely everybody.'Other reviewers, like Daniel Poon, a 27-year-old content creator, review mainstream chains when they release products inspired by other cuisines. He reviewed Pret's ube drink, saying it didn't feel authentic to the original Filipino flavor. Poon appreciates chains' efforts to branch out and try new things, but also values diversity and trying different cuisines.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

TGI Fridays, a global bar-restaurant chain, is set for a UK revival under the leadership of Ray Blanchette, who has acquired the brand's UK arm. Blanchette, a former TGI Fridays kitchen manager, believes the chain can regain its momentum in the UK and expand globally to 1,000 outlets. The UK restaurant industry has faced significant challenges, including higher staffing, energy, and food costs, as well as decreased diner numbers due to financial constraints. However, Blanchette is optimistic about TGI Fridays' prospects, citing its rich history and legacy as a foundation for growth. Blanchette's investment firm, Sugarloaf, has taken control of the global master franchise for TGI Fridays and directly operates 11 US outlets and the UK restaurants. He plans to invest over £2.5m in revamping restaurants, updating kitchen equipment, and enhancing staff training. Blanchette acknowledges that the UK tax regime for high street businesses is 'problematic' and stifles growth. He hopes for government change, given hospitality's significant role as one of the UK's largest employers. The revamped TGI Fridays UK will focus on providing an 'over the top and fun' experience, with a new menu, affordable options, and improved service. Blanchette is confident that a turnaround is possible, having read hundreds of thousands of online reviews of the UK business.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.